Blood was collected by cardiac puncture into tubes containing 3.2% sodium citrate (9:1 v/v) (41.1506.002; Sarstedt, Nümbrecht, Germany). Samples were immediately centrifuged at RT to collect plasma. Plasma was stored at −80 °C until further use. Prothrombin time (PT) and activated partial thrombin time (aPTT) were assessed on an automated coagulation analyzer (CS-2100i) with reagents (PT-Innovin for PT and ActinFS for aPTT) and protocols from the manufacturer (Siemens, Marburg, Germany). Levels of factor V (FV), VII (FVII), and FVIII (FVIII) were determined on an automated coagulation analyzer (CS2100i) based on the one-stage clotting assay with factor-deficient plasma (Siemens, Marburg, Germany). Testing was performed in accordance with the protocols from the manufacturer (Siemens). Levels are denoted as percentages of standard human plasma (Siemens, Marburg, Germany).
Cs2100i
Manufactured by Siemens
Sourced in Germany
The CS2100i is a laboratory equipment product from Siemens. It is designed to perform core functions within a laboratory setting. The detailed specifications and intended use of this product are not available in this response.
Automatically generated - may contain errors
Lab products found in correlation
4 protocols using cs2100i
1
Coagulation Factor Assessment Protocol
2
Establishing New Reference Intervals for dRVVT
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Our laboratory uses LA sensitive aPTT and dRVVT as screening investigations where a clinician suspects the presence of LA. For the purpose of this study, only dRVVT was assessed.
Verification and implementation of reference ranges were inadequate with the change of coagulation analyser to the Siemens CS2100i, and reagents to Siemens LA1 Screening Reagent and LA2 Confirmation Reagent (LA1=screening reagent for dRVVT, LA2=confirming dRVVT reagent). Both these reagents are dRVVT assays, with LA2 having a higher concentration of phospholipids. A new reference interval was established early in 2016, by running specimens obtained from 40 healthy donors. These results were compared to the reference intervals suggested by the manufacturer of the reagents. CLSI 2014 guidelines and guidelines by Siemens for the use of the Siemens CS2100i analyser and reagents were employed. The reference interval, for LA1 screen dRVVT, subsequently changed from 31.89-48.05 seconds to 33.80-43.90 seconds. The reference interval, LA2 confirm dRVVT remained the same, 28.63-36.55 seconds.
Data from all dRVVT assays performed from January 2015 to December 2015 were examined in a cross-sectional study. Due to the unavailability of the newer anticoagulants in public health care in our setting, none of the patients, to our knowledge, in this study was on any of the new oral anticoagulants.
Verification and implementation of reference ranges were inadequate with the change of coagulation analyser to the Siemens CS2100i, and reagents to Siemens LA1 Screening Reagent and LA2 Confirmation Reagent (LA1=screening reagent for dRVVT, LA2=confirming dRVVT reagent). Both these reagents are dRVVT assays, with LA2 having a higher concentration of phospholipids. A new reference interval was established early in 2016, by running specimens obtained from 40 healthy donors. These results were compared to the reference intervals suggested by the manufacturer of the reagents. CLSI 2014 guidelines and guidelines by Siemens for the use of the Siemens CS2100i analyser and reagents were employed. The reference interval, for LA1 screen dRVVT, subsequently changed from 31.89-48.05 seconds to 33.80-43.90 seconds. The reference interval, LA2 confirm dRVVT remained the same, 28.63-36.55 seconds.
Data from all dRVVT assays performed from January 2015 to December 2015 were examined in a cross-sectional study. Due to the unavailability of the newer anticoagulants in public health care in our setting, none of the patients, to our knowledge, in this study was on any of the new oral anticoagulants.
3
Measuring Free Protein S and Activity
Check if the same lab product or an alternative is used in the 5 most similar protocols
Free PS was measured on the Sysmex CS2100i coagulation system by a particle-enhanced immunoassay using the commercial INNOVANCE Free PS Ag kit (Siemens Healthineers, Erlangen, Germany). The reference interval was 0.69–1.37 × 10
3IU/L (locally determined 95% reference interval based on 105 blood donors). PS activity was measured on the ACL TOP 550 system by a clotting method using the commercial Hemosil Protein S Activity kit (Instrumentation Laboratory, Munich, Germany). The reference interval was 0.75–1.40 × 10
3IU/L (locally determined 95% reference interval based on 50 blood donors).
+ Expand
Free PS was measured on the Sysmex CS2100i coagulation system by a particle-enhanced immunoassay using the commercial INNOVANCE Free PS Ag kit (Siemens Healthineers, Erlangen, Germany). The reference interval was 0.69–1.37 × 10
3IU/L (locally determined 95% reference interval based on 105 blood donors). PS activity was measured on the ACL TOP 550 system by a clotting method using the commercial Hemosil Protein S Activity kit (Instrumentation Laboratory, Munich, Germany). The reference interval was 0.75–1.40 × 10
3IU/L (locally determined 95% reference interval based on 50 blood donors).
4
Plasma vWF Activity Measurement
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Blood was collected by cardiac puncture into tubes containing 3.2% sodium citrate (9:1 v/v) (41.1506.002; Sarstedt, Nümbrecht, Germany). Samples were immediately centrifuged at RT to collect plasma. Plasma was stored at −80 °C until use. Von Willebrand ristocetin cofactor (vWF RCF) levels were determined on a CS2100i coagulation analyzer with the Innovance vWF activity kit (Siemens, Marburg, Germany) in accordance with the protocol from the manufacturer with all equipment and reagents from Siemens (Marburg, Germany).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!